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The immobilization of Lipase from Rhizomucor Miehei into hybrid nanospheres containing 6 
a liposomal core, where enzyme is confined, was reported. Organic Liposomal-enzyme 7 
phase was protected by inorganic silica matrix obtained with and without surfactant that 8 
stabilizes the internal organic phase, isolates and protects the bioactive molecules. The 9 
optimized heterogeneous biocatalysts prepared was used for enantioselective esterification 10 
of (R,S)-ibuprofen. The influence of several catalytic parameters on the activity of hybrid 11 
nanospheres (type of solvent, nature of the alcohol, reaction temperature), was investigated. 12 
The best catalytic performances of heterogeneous biocatalysts were showed at 37°C, using 13 
iso-octane as solvent and 1-propanol as alcohol (ester yield value ranging between 78 and 14 
93%). A strong activity and stability (up to 9 reaction cycles) of immobilized enzyme into 15 
hybrid nanospheres, with respect to the free form, was observed: ester yield of free Lipase 16 
is only the 25% in the same reaction conditions. Rhizomucor miehei lipase, both in its free 17 
and immobilized form, only reacts with the S (+) enantiomer of (R, S)–Ibuprofen, in all the 18 
reaction conditions tested. 19 
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1. Introduction 22 
The enzymes are very active and highly specific biocatalysts that make enormous efforts of current 23 
research to obtain catalytic systems with comparable behavior to this type of natural catalysts [1,2]. 24 
Attempts to imitate the enzymatic action through the synthesis of artificial homogeneous or 25 
heterogeneous catalysts have largely been carried out [3-6]. However, the achieved specificity with 26 
these solid porous catalysts is not comparable with the well-known and reported catalytic capacity 27 
of enzymatic systems which exhibit high sterospecificity and regioselectivity due to their 28 
characteristic shape, charge and hydrophobic-hydrophilic properties [7,8]. The direct use of natural 29 
enzymes or their derivatives could be a serious alternative to perform several reaction processes 30 
with high specificity and reactivity. On the other hand, the poor physico-chemical stability of 31 
enzymes seriously limits their employ as effective catalysts because the reaction media conditions 32 
favor their denaturalization and, consequently, their inactivity. Another associated problem would 33 
be the impossibility to recover and reuse the enzymatic systems in successive catalytic cycles [9-34 
10]. To overcome these obstacles would come from the isolation and stabilization of active 35 
enzymes into inorganic matrixes or organic systems which presumably provide an elevated 36 
protection, allowing the enzymatic action and preserving their associated catalytic activity and 37 
selectivity [11-23]. Among these, Liposome can be used to largely been used to encapsulated 38 
enzyme [24-27]. However, Liposomes show important limitations regarding to their poor 39 
hydrothermal and chemical stability that would favor the rapid denaturation of encapsulated 40 
enzymes [28-31]. The alternative approach could be the protection of the liposomal phase with 41 
external inorganic shells, such as porous silica [32-35]. In this case, the hydrothermal stability of 42 
silica would protect the internal enzymatic – liposomal system and its external porosity would allow 43 
the interaction with the reaction media. Furthermore, the associated structural role of organized 44 
phosphatidylcholine micelles, which are forming the liposomes, as surfactants, would facilitate the 45 
generation of external porous silica layers around of spherical liposomes. Specifically, these 46 
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nanospheres would be composed of a purely organic internal liposomal phase in which bioactive 47 
enzymes are encapsulated. Covering this part, an external self-assembled porous silica shell would 48 
be present, stabilizing the internal liposomal phase and, consequently, isolating and protecting the 49 
enzymes [36].  This methodology was successfully used to obtain organic-inorganic nanospheres 50 
with responsive external molecular gates, localized in the outer silica shell, for effective drug 51 
storage and controlled release [37].   52 
Recently we describe a effective biocatalysts prepared through the encapsulation of liposome – 53 
lipase systems onto porous silica nanoparticles for biodiesel production [38]. In spite of previous 54 
work, in this study we optimized the synthesis procedure of  heterogeneous biocatalyst  in order to 55 
improve the stability of immobilized Rhizomucor miehei Lipase. The influence of several 56 
experimental factors, such as silica/liposome weight ratio and mixing time between liposome and 57 
lipase, was studied. At this point, the additional use of templating agent (Hexadecylamine)  during 58 
the core liposome coverage by silica, has made possible the creation of mesoporous silicic shell 59 
with properties to allow reagent and product diffusion.  60 
The catalytic performance and the stability of optimized heterogeneous catalysts was evaluated in a 61 
enantioselective esterification of racemic ibuprofen (Figure 1), in order to produce active 62 
enantiomer from racemic product.  In the last year, there was an increasing trend toward the use of 63 
Lipase for a production of enantiomerically pure compounds [39-48], particularly in a chiral 64 
resolution of (R,S)-ibuprofen [49-59]. In particularly, Immobilized Rhizomucor miehei lipase 65 
shows to have adequate stability and biosynthetic capabilities for a chiral resolution of (R,S)-66 






2. Materials and Methods 68 
2.1. Materials 69 
Organic nanospheres preparation. For the preparation of organic parts of nanospheres, L-α-70 
phosphatidylcholine has been used as lecithin liposome precursor, purchased from Sigma Aldrich, 71 
while commercial lipase solution, PALATASE 20000L (Novo Nordisk Denmark), has been used as 72 
enzyme. This enzyme is a purified 1,3-specific lipase (EC 3.1.1.3) from Rhizomucor miehei (RML). 73 
Silica porous shell preparation. For the preparation of silica porous shell, tetraethyl orthosilicate 74 
(99%), as silica source, hexadecylamine (98%), as template, sodium fluoride (99%), as mineralizing 75 
agent, have been used. All of these products were purchased from Sigma Aldrich. 76 
Reactants for Catalytic Test: For the reaction tests, different alcohols have been tested: methanol 77 
(99.9%), 1-Propanol (99.9%), 1-butanol (99.9%). While isooctane (99.9%) and dimethylformamide 78 
(99%), have been tested as reaction solvents. Racemic Ibuprofen (98 %) and its pure enantiomers 79 
(R and S), have been purchased from Sigma-Aldrich. 80 
  
2.2.  Hybrid Nanospheres Synthesis Method: Enzyme immobilization procedure. 81 
The synthesis of hybrid nanospheres take place through two consecutive steps. In the first 82 
step preparation of liposomal phase containing  Rhizomucor miehei lipase was carried out 83 
and the influence of two important synthesis parameters was evaluated: silica/liposome 84 
weight ratio and mixing time of liposome/lipase solution. In the second step, formation of 85 
porous silica shell around the liposomal phase was performed: an amount of TEOS was 86 
added in the liposome/lipase solution at room temperature for 24 hours.  After this time, an 87 
amount of sodium fluoride (7.1 mg) was incorporated to initializing the condensation of 88 
silane groups and the stirring was maintained for 48 h at room temperature. In order to 89 
synthesized different sample, templating agent was used during the core liposome coverage 90 
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by silica. An amount of hexadecylamine (tetraethyl orthosilicate/hexadecylamine molar ratio 91 
equal to 4) was dissolved in a 40 ml of ethanol. The hexadecylamine solution was added 92 
drop-wise 24 h after the addition of TEOS, with vigorous stirring at room temperature for 24 93 
hours. 7.1 mg of NaF was incorporated and stirring for 48 h at room temperature. Later on, 94 
the sample was centrifugated and the recovered solid was washed with distillated water and 95 
dried at 30 °C overnight. All prepared catalysts were activated by washing with 100 ml of 96 
solvent (isooctane) and 900 ml of distillated water, and dried at 30 °C overnight. 97 
The total protein concentration of the initial and final solution was calculated using UV absorption 98 
method at 235/280 nm [63], and the quantity of protein adsorbed on the support was determined by 99 
a mass balance between initial and final solution. 100 
 
2.3. Catalyst Characterization 101 
Thermogravimetric and Differential Thermal Analysis. TGA-DTA curve were recorded in 102 
nitrogen stream with a Metler Toledo TGA/SDTA 851E instrument. Measurements were 103 
effectuated in a temperature range between 20 and 800°C, with heating rate of 10°C/min and 104 
in synthetic air stream with a flow of 50mL/min. 105 
Fluorescence Confocal Microscopy. LEICA TCS-SL is the imaging core’s point-scanning 106 
laser confocal system and it was used to clarify with greater accuracy the exact position of 107 
the enzyme inside the nanospheres. In order to perform the analysis, during the nanospheres 108 
synthesis process, lipase was mixed with a fluorescent compound (fluorescein 109 
isothiocyanate (99%)) for 2 hours.  110 
Transmission Electron Microscopy. Transmission electron microscopy (TEM) micrographs 111 
were obtained with a Philips CM10 electron microscope operating at 100 KeV.  112 
13C NMR and 29Si NMR. Spectra have been recorded at room temperature under magic angle 113 
spinning (MAS) in a Bruker AV-400 spectrometer. The single pulse 29Si spectra were 114 
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acquired at 79.5 MHz with a 7 mm Bruker BL-7 probe using pulses of 3.5 µs corresponding 115 
to a flip angle of 3/4 π radians, and a recycle delay of 240 s. Pulses of 0.5 µs to flip the 116 
magnetization π/20 rad, and a recycle delay of 2 s were used. The 13C spectra were recorded 117 
with a 7 mm Bruker BL-7 probe and at a sample spinning rate of 5 kHz. 13C and 29Si were 118 
referred to adamantine and tetramethylsilane, respectively.  119 
N2 adsorption/desorption. Nitrogen adsorption isotherms were measured at -196 ºC with a 120 
Micromeritics ASAP 2010 volumetric adsorption analyser. Before analyses, all samples 121 
were calcinated at 600°C under vacuum condition for 8 hours, and outgassed for 12 h at 100 122 
ºC.  123 
Powered X-ray Diffraction (XRD). This analysis were performed by powered X-ray 124 
diffraction technique using Philips X'PERT diffractometer. Data were collected stepwise 125 
over the 2° ≤ 2ϑ ≤ 20°C angular region, with steps of 0.01° 2ϑ, 20-s/step accumulation time 126 
and Cu Kα (λ= 1.54 Å) radiation. 127 
 
2.4. Catalytic Test 128 
2.4.1 Enantioselective esterification procedure. 129 
The standard reaction mixture was composed of organic solvent (10 mL), racemic ibuprofen 130 
(66 mM) and alcohol (66 mM), without addition of water. The reaction started by the 131 
addition of prepared heterogeneous biocatalyst (7%wt of lipase with respect to ibuprofen) to 132 
the solution and carried out in 50 mL conical flask, under orbital magnetic stirring at 135 133 
rpm and at different temperature. Samples of 50 µL of the solution were withdrawn at 134 
different times and diluted in 50 µL of isooctane. The amount of ester (ester yield) formed 135 
during the reaction and the enantiomeric excess were determined by gas chromatography 136 




2.4.2. Analytical procedures of reaction products. 138 
Gas Chromatography Analysis. This technique has been performed in an Agilent 7890A, equipped 139 
with flame ionization (FID) and mass spectrometry detectors. The column used was a BP5MS with 140 
low polarity phase (5%-phenyl-95%-polysilphenylene-siloxane; 30m x 250 µm x 0.25 µm). The 141 
injector and the detector temperatures have been, respectively, of 280°C and of 300°C. The carrier 142 
gas was nitrogen, with a flow rate of 25 mL/min. The temperature program of the column was: 2 143 
min at 50°C and 30°C/min until 280°C. Ester yield was calculated in accordance with the equation 144 
(1): 145 






�  * 100                (1) 146 
Where the 𝐴𝐴𝐸𝐸  and PME  are the peak area an molecular weight of the (S)-ester of ibuprofen (desired 147 
product) respectively, while  Aib and PMib  are respectively, the peak area  and molecular weight of  148 
ibuprofen. The quantitative analysis to measure formed ester and remaining acid was carried out 149 
using internal standardization method. 150 
Turnover number (TON) and turnover number of frequency (TOF) were also calculated in 151 







�          [/]             (2) 153 
𝑇𝑇𝑇𝑇𝑇𝑇 = 𝑇𝑇𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇
       [ℎ−1]               (3) 154 
Chiral Analysis. .This analysis was performed using a chiral gas chromatograph (Agilent 8000S) 155 
equipped with FID and with a BETADEXTM120 column (35%-phenyl-65%-dimethylsiloxane; 30m 156 
x 0.25 mm x 0.25µm). The injector and the detector temperatures have been, respectively, of 280°C 157 
and of 300°C. The carrier gas has been nitrogen, with a flow rate of 25 mL/min. The temperature 158 
program of column was 20 minutes  at 50°C; 5°C/min until 140°C; 20 minutes at 140°C; 5°C/min 159 
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until 210°C  and 20 minutes at 210°C. The retention times observed Enantiomeric excess (ee) was 160 
calculated according to the equation (4): 161 
𝑒𝑒𝑒𝑒 % = 𝑅𝑅−𝑆𝑆
𝑆𝑆+𝑅𝑅
 ∗ 100            For R > S             (4) 162 
where R is the peak area for the R(-) enantiomer of ibuprofen (retention times equal to 76 min)  and 163 
S is the peak area for the S(+) enantiomer of ibuprofen (retention times equal to 76.4 min).  164 
 
3. Results and Discussion 165 
3.1 Characterization catalysts results 166 
The  influence of two important synthesis parameters, silica/liposome weight ratio and mixing time 167 
of liposome/lipase solution, on the quantity of immobilized enzyme and on the morphology of 168 
nanospheres, were evaluated. Table 1 summarizes these specifications, for each prepared catalysts. 169 
The tendency of enzyme immobilization quantity towards liposome/lipase solution mixing time, for 170 
each liposome/silica ratio tested, was reported in Figure 2. It is immediately evident that the mixing 171 
time between liposome and lipase strongly affects the amount of immobilized enzyme (Figure 2a). 172 
Particularly, after only 2 h, for each Silica/Liposome ratio tested, the highest Lipase immobilized 173 
amount was obtained. Increasing the mixing time, the amount of retained enzyme decrease probably 174 
due to the damage/break of liposomal shell. Moreover, for the same liposome/lipase mixing time, 175 
the specific amount of immobilized enzyme strongly increased when the SiO2 amount used was 176 
lower, as expected (Figure 2b).   177 
As Shown by TEM analysis result (Figure 3), also the morphology of the samples was strongly 178 
affected by the two changed parameters. The equal o lower amount of SiO2 with respect to the 179 
liposome (NS2 and NS3 samples) does not permits the complete single liposome sphere coverage 180 
by the silica shell (Figure 3a), in fact more spheres are included in an unique silica shell. Increasing 181 
time mixture between lipase and liposome,  the damage/break and the opening of liposomal shells 182 
occurs (Figures 3b and 3c, respectively for NS2 and NS3 samples).   183 
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On the contrary, perfect coverage of liposomal cells by the silica shell can be observed where the 184 
amount of silica is double respect to the amount of Liposome (sample NS1), both for low (2 hours) 185 
and high (12 hours) mixing time between liposome and lipase (Figure 4(a) and (b), respectively). 186 
However, in this last case, the quantity of immobilized enzyme is very low, probably because only 187 
few liposome cells remain unaltered after this long mixing time. 188 
It is possible to conclude that the optimal hybrid nanospheres were obtained by a double amount of 189 
silica with respect to liposome quantity and after only 2 hour of mixing time between liposome and 190 
lipase (Figure 4(a)), represented by NS1 sample that was selected as reference catalyst and analyzed 191 
with more details. First of all, in order to clarify more accurately the exact position of the enzyme 192 
inside the optimized nanospheres of sample NS1, fluorescence confocal microscopy analysis was 193 
carried out. This analysis confirm that, the enzyme is distributed inside the internal liposomal phase 194 
and the organic liposome/lipase phase has been protected by inorganic matrix (Figure 5). 195 
The optimized procedure (SiO2/Liposome weight ratio equal to 2 and the optimum liposome/lipase 196 
solution mixing time equal to 2 hours) was used also to prepare different hybrid nanospheres 197 
(NSH1 sample), using surfactant to create silica shell. In Table 2 the synthesis conditions are 198 
reported. The use of surfactant does not affect the final conformation of the nanospheres and the 199 
position of the enzyme, which results perfectly confined inside the liposomal (Figure 6). Moreover, 200 
to get more information about the external silica structure of this sample, XRD and TEM analysis 201 
was carried out (For XRD results see Supporting Information: Section A). With respect to the 202 
nanospheres synthesized without surfactant (in which the external silica shell is amorphous, as 203 
corroborate by XRD pattern – results not shown), the silica shell of NSH1 sample exhibits a typical 204 
worm-hole structure characterized by parallel channels to the support surface (Figure 7).  205 
Other characterization tests were carried out in order to give more information about optimized 206 




3.2. Catalytic test results 208 
3.2.1. Influence of catalyst composition 209 
Catalytic test to evaluate the role of Liposome and Hexadecylamine in the reaction, were carried 210 
out. See Supporting Information: Section B for more details. The results confirm that no reaction 211 
between ibuprofen and liposome or ibuprofen and hexadecylamine occurs. 212 
 
3.2.2. Influence of the alcohol 213 
It is recognized that lipase from Rhizomucor miehei works better in esterification of primary 214 
alcohols, whereas its activity is lower with secondary alcohols and is inactive with tertiary alcohols 215 
[64]. With the aim of studying the effect of alcohol nature on our esterification reaction, the 216 
attention was directly focused on the study of the influence of primary alcohols with different chain 217 
lengths, i.e, methanol, 1-propanol and 1-butanol.  The results are shown Table 3. The stereobias (S-218 
(+)-preference) is the same for all the nucleophiles tested. However the catalyst performance is 219 
strong influenced by the length of the used alcohol. With 1-butanol and methanol, immobilized 220 
Rhizomucor miehei lipase shows low activity, probably due to the different substrate specificity of 221 
the lipase and/or to the different substrate solvation of the alcohol, as also suggested by previous 222 
studies [65]. The highest enantiomeric excess (ee), ester yield and turnover numbers (TON and 223 
TOF) are obtained in the reaction where 1-propanol is used as alcohol. In the Supporting 224 
Information: Section B, the progress and the whole time profile of the reaction carried out in 225 
presence of 1-propanol, monitored by chiral gas chromatography, was reported. 226 
 
3.2.3. Influence of the Temperature. 227 
The effect of temperature, in the range from 27 to 80 °C, on the enzyme activity in the 228 
enantioselective esterification of (R,S)-ibuprofen was examined. As consequence of previous 229 
results, all catalytic tests were carried out in presence of 1-propanol as alcohol. At all temperature 230 
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tested Rhizomucor miehei Lipase shows S-(+)-enantiorecognition. The results were reported in 231 
Table 4. We can observe that the highest ester yield and turnover numbers was obtained at 37°C, 232 
decreasing at higher temperature due to the modification of the active center geometry of enzyme.  233 
In order to avoid the evaporation of the organic solvent and to obtain a higher ester yield of the 234 
desired product, the optimum temperature in the esterification of Ibuprofen was fixed at 37 °C. 235 
 
3.2.4. Influence of the Solvent nature. 236 
The influence of the solvent nature on the catalytic efficiency of enzymes was also studied. Beyond 237 
using a-polar isooctane solvent, the activity of immobilized Rhizomucor miehei Lipase in the 238 
presence of polar solvent, dimethylformamide (DMF), was tested. The polar DMF totally 239 
deactivates the enzyme contained into NS1 catalyst (Figure 8), due to the removal of the necessary 240 
water for maintaining the native and active conformation of the enzyme. On the contrary, 241 
hydrophobic solvents, due to their lower tendencies to strip essential water in the micro-242 
environment of enzyme, allow preserving their activity. 243 
 
3.4. Stability of catalysts 244 
After selection of the best reaction conditions: temperature 37°C; 1-propanol as alcohol; iso-octane 245 
as a solvent, a "leaching test" was carried out in order to verify if  there is a leaching after the first 246 
catalytic use of the optimized catalysts. So, after 1 hour, the reaction was stopped, the catalyst was 247 
separated from the liquid reaction media and the reaction was again carried out without catalyst. 248 
The time reaction profile was compared with time reaction profile of standard reaction (see 249 
Supporting Information: Section C). When the NS1 catalyst was removed, the ester yield does 250 
not increase significantly after the first hour of reaction (lower than 5 %). So, no significant enzyme 251 
leaching occurs.  252 
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At this point, the residual esterification activity under optimal reaction conditions of NS1 and NSH1 253 
catalyst, after repeated catalytic uses, was analyzed. In Figure 9, the stability results after 9 reaction 254 
cycles for both catalysts, were reported. Immobilized lipase in the NS1 catalyst retains its activity 255 
with moderate loss:  lower than 3% after 4 reaction cycles; lower than 11% after 5 reaction cycles. 256 
After nine cycles, the lipase immobilized into NS1 catalyst retains almost the 45% of its initial 257 
esterification activity. For NSH1 sample the activity loss was lower than 3% after 4 reaction cycles;  258 
lower than 18% after 8 reaction cycles. After nine cycles, the lipase immobilized into NSH1 259 
catalyst retains almost the 60% of its initial esterification activity and the external mesoporous 260 
structure of  NSH1 catalyst was maintained (Figure 10). The NSH1 show the best catalytic 261 
performance most probably because the mesoporous structure of its external silica shell facilitates 262 
the mass transfer of substrate and products. However, for both sample, immobilized is stable after 263 
repeated catalytic cycles and the enzyme remains linked to the phospholipids layer inside the 264 
liposome and is still present in the nanospheres (Figure 11).   265 
 
3.3. Comparison with Free Lipase. 266 
Comparison between free and immobilized enzyme performances, was carried out. The results are 267 
reported in Figure 12(a) and (b). Both catalysts, NS1 and NSH1, show better performance with 268 
respect to the free lipase. Particularly, NSH1 sample shows the best one probably because the 269 
mesoporous structure of its external silica shell facilitates the mass transfer of substrate and 270 
products. Rhizomucor miehei Lipase reacts better only with the S-(+) enantiomer of (R,S)-271 
ibuprofen both in it immobilized and free form. 272 
 
4. Conclusion 273 
Novel organic–inorganic nanospheres formed by a hybrid silica shell (with an internal liposomal 274 
core) containing bioactive molecule (lipase enzyme) were successfully synthesized. The highest 275 
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immobilized enzyme amount and the best nanospheres morphology were obtained using a 276 
SiO2/Liposome ratio equal to 2 and a Lipase/Liposome mixing time equal to 2 hours.  277 
Hybrid nanospheres with mesoporous external silica shell have also been synthesized by use of 278 
hexadecylamine as surfactant in the polymerization of silica shell. Heterogeneous biocatalysts were 279 
used in the enantioselective esterification of ibuprofen. Many factors affect the enzyme activity in 280 
the esterification reaction. The optimal conditions for the esterification of ibuprofen using hybrid 281 
nanospheres containing Rhizomucor miehei Lipase as biocatalyst are: temperature = 37°C, alcohol = 282 
1-propanol, solvent = iso-octane and ibuprofen/alcohol molar ratio equal to 1. 283 
Catalyst with mesoporous external silica shell shows better catalytic performance with respect to 284 
that one synthesized without surfactant. Most probably, the mesoporous channel facilitates the 285 
substrate and product mass transfer during the reaction. Finally, the stability of immobilized lipase 286 
is very high: up to 9 reaction cycles, at least. The high stability of the heterogeneous biocatalyst 287 
produces an immobilized enzyme productivity c.a. 15÷16 times higher than that of its free form.  288 
Optimized catalysts and selected best reaction conditions lead a simple and efficient 289 
enantioselective synthesis of (S)-enantiomer of ibuprofen, being a potential application in the 290 
pharmaceutical industry. The high-efficiency catalytic system here proposed could be used in a next 291 
future for various enzymatic/chemical processes, like multi-enzymatic cascade reaction, drug and 292 
gene delivery and biosensors.  293 
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